Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JNF7 | ISIN: SE0011311554 | Ticker-Symbol: DH1
Frankfurt
24.01.25
08:12 Uhr
0,008 Euro
-0,001
-14,58 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
DIVIO TECHNOLOGIES AB Chart 1 Jahr
5-Tage-Chart
DIVIO TECHNOLOGIES AB 5-Tage-Chart
GlobeNewswire (Europe)
91 Leser
Artikel bewerten:
(0)

Divio Technologies AB: Divio Technologies (AB) publishes preliminary financial key figures for the period 1 July - 30 September with an MRR growth of 39%.

Finanznachrichten News

As part of the announced fund raise Divio is releasing preliminary financial numbers for the financial quarter ending 30th September 2024 (Q3).

Net sales grew by 8% year over year driven by deeper engagement of existing clients and new client subscriptions. MRR (monthly recurring revenues) increased by 39% over the same period primarily driven by the signing of a major Swiss Healthcare Company as announced on the 9th of September 2024. The consultancy engagement of the new contract, with ca 59 KUSD in additional monthly revenue, has not been included in the MRR KPI as it is classified as professional service revenue and operates with a low margin. As the project started at the end of the quarter, no material revenue has yet been recognized during the period.

Costs have been adjusted and remain stable compared to the same period last year, which is a result of keeping control over staffing and other external costs. The goal is to achieve additional cost reductions moving forward. This led to an EBITDA improvement of approximately 19% from -2.1 MSEK to -1.7 MSEK. EBIT improved from -3.6 MSEK (-3.3).

The total result for the period was -0.3 MSEK (-4.4) which was all attributed to improved FX gains on balance sheet items.

Cash position amounted to 1.2 MSEK awaiting some payments from customers, especially the first payment from the Swiss Healthcare Company as described above. The cash position includes 2.0 MSEK drawn under the loan facility entered with Levin Invest AB on the 9th of September 2024.

Divio recently announced a 100% guaranteed rights issue of MSEK 15.5 before issuance costs. The subscription price is SEK 0.12 per share and the subscription period is 29th October to 12th November 2024. This capital raise will strengthen the company's equity, providing funding until the next payment from Fidelity and positioning the company to reach cash flow positivity.



Third quarter (3M)
Year to date (9M)
MSEK
20242023%
20242023%
Key Financials







Subscription revenue
5.34.810%
15.113.611%
Professional services revenue
0.10.10%
0.61.1-45%
Net sales
5.45.08%
15.614.76%
Total revenue
7.26.86%
20.919.19%
Costs
-8.9-8.90%
-29.5-25.0-18%
EBITDA
-1.7-2.119%
-8.5-5.9-44%
Dep / Am
-1.6-1.5-7%
-4.7-4.5-4%
EBIT
-3.3-3.68%
-13.3-10.4-28%
Profit for the period
-0.3-4.493%
-12.8-9.8-31%
EPS before dilution (SEK)
-0.00-0.03-
-0.07-0.06-









MRR (KUSD)
21015139%



Cash position
1.220.8-94%



Jon Levin, CEO of Divio, commented: "We are pleased to share our preliminary Q3 2024 numbers, which are in line with our expectations, showing an 39% increase in MRR. Our new enterprise customer lays the foundation for the next phase of Divio's growth and further validates the strength of our service offering."

The full Q3 quarterly report is scheduled to be released on 29th November 2024.

Press enquiries

For further information about Divio Technologies, please visit divio.com or contact CEO Jon Levin (ir@divio.com)
The company's Certified Adviser is FNCA Sweden AB.

About Divio Technologies

Divio Technologies AB (Publ) is the PaaS and Cloud Management Software development group behind the Divio platform, which simplifies cloud hosting, deployment and development via a PaaS solution. The platform allows enterprises to reduce costs, time to market and the burden on employees, as well as decreasing dependency on cloud vendors.

This information is information that Divio Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-28 23:05 CET.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.